Science Corporation, a neurotechnology startup founded by Neuralink co-founder Max Hodak, has raised $230 million in a Series C funding round to accelerate the development and commercialization of its brain–computer interface technologies.
The round included participation from investors such as Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT. The funding gives the company a reported post-money valuation of approximately $1.5 billion and brings its total funding to about $490 million.
What The Company Does
Science Corporation develops neural interface technologies designed to treat neurological and sensory disorders. The company focuses on brain–computer interfaces (BCIs), systems that enable communication between the brain and electronic devices.
Its most advanced product is PRIMA, a retinal implant designed to help restore vision for patients suffering from advanced macular degeneration. The device is a microchip smaller than a grain of rice that is surgically implanted in the eye.
PRIMA works in combination with a pair of glasses equipped with a camera. The camera captures visual information, which is then converted into signals transmitted to the implanted chip. These signals stimulate the retina and allow the brain to interpret visual patterns, helping patients recover a degree of functional vision.
Science Corporation acquired the technology behind PRIMA in 2024 when it purchased the assets of French company Pixium Vision. Since then, the company has refined the system and continued the clinical development program that Pixium had initiated.
According to the company, clinical trials involving 47 patients across Europe and the United States have shown promising results. Around 80 percent of participants demonstrated measurable improvements in visual acuity and were able to identify letters, numbers, and words.
Advertisement
Market Context / Industry Background
Brain–computer interface technologies have gained increasing attention in recent years as advances in neuroscience, microelectronics, and artificial intelligence enable new ways to connect neural signals with digital systems.
Several startups and research organizations are developing implantable or wearable systems designed to restore lost sensory functions, treat neurological disorders, or enable communication for patients with paralysis.
While many companies in the BCI field remain in experimental stages, the development of clinically approved devices could mark a significant milestone for the sector. Achieving regulatory approval and commercial deployment remains one of the major challenges for neurotechnology companies.
Vision restoration has emerged as one of the early clinical applications of neural interface technologies. Diseases such as age-related macular degeneration affect millions of people worldwide and currently have limited treatment options once severe vision loss occurs.
By combining implantable devices with external computing systems, companies in this field aim to create assistive technologies capable of restoring partial sensory function.
Founder / Investor Commentary
Science Corporation founder Max Hodak has positioned the company as one of the neurotechnology startups seeking to bring brain–computer interface products to market in the near term.
The company believes the PRIMA implant could become one of the first commercially available BCI-based medical devices, depending on the outcome of ongoing regulatory processes.
Clinical data collected during the trials has provided early evidence that the technology can help patients recover certain visual capabilities, which the company views as an important step toward broader applications of neural interface systems.
Growth Plans / Use Of Funds
Science Corporation plans to use the Series C funding to support the commercialization of the PRIMA implant and expand its clinical research programs.
The company has submitted a CE mark application for the PRIMA system in the European Union and expects a potential regulatory decision around mid-2026. If approved, the device could be introduced in European markets shortly afterward.
Germany is expected to be among the first markets where the technology may become available due to established pathways that allow early access to innovative medical devices. In the United States, the company said discussions with the Food and Drug Administration are ongoing.
Science Corporation is also expanding clinical trials to evaluate PRIMA’s use in other retinal diseases, including Stargardt disease and retinitis pigmentosa, both inherited conditions that can cause progressive vision loss.
Beyond vision restoration, the company is investing in additional neurotechnology research. One program focuses on biohybrid neural interfaces that involve growing engineered neurons from stem cells on a device placed on the brain’s surface. The goal is to create biological connections with existing neural circuits.
Science Corporation has also launched a new internal program called Vessel, which is developing portable organ preservation technology. The system aims to use compact perfusion devices to maintain organs outside the body during transportation or storage.
The company currently employs approximately 150 people as it continues expanding its research and development efforts.
About Science Corporation
Science Corporation is a neurotechnology company focused on developing brain–computer interface systems and medical technologies for neurological and sensory conditions. Founded by Max Hodak, the company conducts research in neural implants, biohybrid interfaces, and organ preservation technologies. Its lead product, the PRIMA retinal implant, is designed to restore functional vision for patients suffering from advanced retinal diseases.
